|
|
Volumn 532, Issue 7598, 2016, Pages 162-164
|
|
Cocktails for cancer with a measure of immunotherapy
a
a
NONE
(United States)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CANCER VACCINE;
IPILIMUMAB;
NIVOLUMAB;
ANTINEOPLASTIC AGENT;
CD40 ANTIGEN;
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;
MONOCLONAL ANTIBODY;
ADVANCED TECHNOLOGY;
CANCER;
DRUG;
IMMUNE SYSTEM;
IMMUNOASSAY;
RESEARCH WORK;
THEORETICAL STUDY;
TUMOR;
ADVANCED CANCER;
ARTICLE;
AUTOIMMUNITY;
CANCER IMMUNOTHERAPY;
CANCER RESEARCH;
CANCER SURVIVAL;
COMBINATION DRUG THERAPY;
HUMAN;
IMMUNE RESPONSE;
IMMUNE SYSTEM;
MELANOMA;
NONHUMAN;
PRIORITY JOURNAL;
REMISSION;
T LYMPHOCYTE;
TREATMENT RESPONSE;
ANIMAL;
ANTAGONISTS AND INHIBITORS;
BIOASSAY;
CHILD;
CLINICAL TRIAL (TOPIC);
DRUG EFFECTS;
GENETIC EPIGENESIS;
IMMUNOLOGY;
IMMUNOTHERAPY;
MORTALITY;
MOUSE;
NEOPLASMS;
PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;
SURVIVOR;
TRENDS;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTIGENS, CD40;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CANCER VACCINES;
CHILD;
CLINICAL TRIALS AS TOPIC;
CTLA-4 ANTIGEN;
ENDPOINT DETERMINATION;
EPIGENESIS, GENETIC;
HUMANS;
IMMUNOTHERAPY;
MELANOMA;
MICE;
NEOPLASMS;
PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;
SURVIVORS;
T-LYMPHOCYTES;
|
|
EID: 84964447054
PISSN: 00280836
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/532162a Document Type: Article |
|
Times cited : (47)
|
|
References (5)
|
